TrialThe Lancet. Respiratory medicine2021

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.

Jürgen Behr et al.PubMed ↗Publisher ↗

No numbers read from the abstract.